Immunotherapies involving monoclonal antibodies targeting programmed death-1 (carrezumab and pembromezumab) offer an alternative for patients with NSCLC in second-line therapy.[5–7] Several elegant global trials have shown that anti-programmed cell death 1 or immune checkpoint inhibitors combined with chemotherapy significantly improve progression-free survival and overall survival in advanced non-squamous NSCLC compared with chemotherapy alone, regardless of programmed death-1 expression levels.[8–10]. Here, PDCD1 is linked to non-small cell lung carcinoma.